The use of a single-component vaccine from Russia, Sputnik Lite, has been approved in Palestine, the Russian Direct Investment Fund (RDIF) said.

"The Russian Direct Investment Fund announces the registration of the Russian single-component vaccine against coronavirus Sputnik Lite by the Ministry of Health of the State of Palestine," the statement said.

The Sputnik V vaccine was previously registered in the country.

According to RDIF CEO Kirill Dmitriev, the approval of the drug will allow Palestine to vaccinate a large number of residents in a short period of time and build up population immunity faster.

The Sputnik Lite vaccine is the first component (recombinant human adenovirus serotype 26 (rAd26)) of the Sputnik V vaccine. The efficacy of the single-component Sputnik Lite vaccine is 79.4% from day 28 after immunization.

Made in Russia // Made in Russia

Author: Karina Kamalova